Compare PAR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | CNTA |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 6.1B |
| IPO Year | 1995 | 2021 |
| Metric | PAR | CNTA |
|---|---|---|
| Price | $15.31 | $39.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $33.20 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $455,547,000.00 | $15,000,000.00 |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $10.95 |
| 52 Week High | $72.15 | $40.26 |
| Indicator | PAR | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 70.14 |
| Support Level | $12.32 | $39.36 |
| Resistance Level | $22.48 | $39.86 |
| Average True Range (ATR) | 0.93 | 0.09 |
| MACD | 0.10 | -0.19 |
| Stochastic Oscillator | 82.25 | 67.19 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.